We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App

AI Model Predicts Patient Outcomes across Multiple Cancer Types

By LabMedica International staff writers
Posted on 07 Dec 2023
Print article
Image: The progression of a tumor can also reflect epigenetics factors that determine the DNA’s structural conformation (Photo courtesy of 123RF)
Image: The progression of a tumor can also reflect epigenetics factors that determine the DNA’s structural conformation (Photo courtesy of 123RF)

In previous research, scientists have examined the impact of mutations in the genes that encode epigenetic factors — elements that influence gene activation or deactivation — on cancer susceptibility. However, understanding the influence of these factors' levels on cancer progression has remained largely unexplored. Addressing this gap, researchers have now developed a groundbreaking artificial intelligence (AI) model based on epigenetic factors that successfully forecasts patient outcomes across various cancer types. It does so by analyzing the gene expression patterns of epigenetic factors within tumors, and categorizing them into distinct groups. This method has been shown to predict patient outcomes more effectively than conventional metrics like cancer grade and stage. Moreover, these insights provide a foundation for future therapies targeting epigenetic factors in cancer treatment, such as histone acetyltransferases and SWI/SNF chromatin remodelers.

Researchers from UCLA Health (Los Angeles, CA, USA) examined the expression patterns of 720 epigenetic factors in tumors from 24 different cancer types. They classified these tumors into unique clusters based on these patterns. Their study revealed that in 10 of these cancer types, the clusters correlated with significant differences in patient outcomes, including progression-free survival, disease-specific survival, and overall survival. This correlation was particularly pronounced in adrenocortical carcinoma, kidney renal clear cell carcinoma, brain lower-grade glioma, liver hepatocellular carcinoma, and lung adenocarcinoma. In these cases, clusters indicating poorer outcomes generally showed higher cancer stages, larger tumor sizes, or more advanced spread.

The researchers then used epigenetic factor gene expression levels to train an AI model, aiming to predict patient outcomes specifically in the five cancer types where survival differences were most significant. The model was able to accurately segregate patients into two groups: those likely to have better outcomes and those facing poorer outcomes. Notably, the genes most critical to the AI model's predictions significantly overlapped with the cluster-defining signature genes.

“Our research helps provide a roadmap for similar AI models that can be generated through publicly-available lists of prognostic epigenetic factors,” said the study’s first author, Michael Cheng, a graduate student in the Bioinformatics Interdepartmental Program at UCLA. “The roadmap demonstrates how to identify certain influential factors in different types of cancer and contains exciting potential for predicting specific targets for cancer treatment.”

Related Links:
UCLA Health 

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Hemoglobin Testing System

Print article


Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The new tests seek to detect mutant DNA in blood samples, indicating the presence of cancer cells (Photo courtesy of Christian Stolte/Weill Cornell)

Advanced Liquid Biopsy Technology Detects Cancer Earlier Than Conventional Methods

Liquid biopsy technology has yet to fully deliver on its significant potential. Traditional methods have focused on a narrow range of cancer-associated mutations that are often present in such low quantities... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.